Glenmark Pharmaceuticals has informed that the company has attached media release on 23rd December 2020, titled ‘Glenmark Pharmaceuticals and Menarini enter into Exclusive Licensing Agreement for commercializing Ryaltris™ Nasal Spray across numerous markets throughout Europe’ which is self explanatory.
The above information is a part of company’s filings submitted to BSE.